| Literature DB >> 30065813 |
Heshu Abdullah-Koolmees1, Helga Gardarsdottir1, Lotte A Minnema1, Kamjar Elmi1, Lennart J Stoker1, Judith Vuyk2, Laurette E Goedhard2, Toine C G Egberts1, Eibert R Heerdink1.
Abstract
BACKGROUND: Prediction of rehospitalization in patients treated with antipsychotics is important for identifying patients in need of additional support to prevent hospitalization. Our aim was to identify factors that predict rehospitalization in patients treated with antipsychotics at discharge from a psychiatric hospital.Entities:
Keywords: BMQ; Rehospitalization; antipsychotic adherence; health care professionals’ expectation; prediction models; psychotic disorder
Year: 2018 PMID: 30065813 PMCID: PMC6058452 DOI: 10.1177/2045125318762373
Source DB: PubMed Journal: Ther Adv Psychopharmacol ISSN: 2045-1253
Figure 1.This scatter plot shows the distribution of patient’s scores of the BMQ (Beliefs about Medicine Questionnaire) specific statements in the four belief groups: accepting, ambivalent, skeptical, and indifferent.
The x axis represents the scores of the necessity subscale and the y axis the scores of the concerns subscale.
Demographic and patient/disease characteristics at discharge.
| Characteristics |
| %/SD/range |
|---|---|---|
| Total | 87 | |
| Mean age, years (SD) | 38.4 | 12.1 |
| Sex (%) | ||
| Male | 52 | 59.8% |
| Diagnosis of psychotic disorder (%) | ||
| Brief psychotic disorder | 18 | 20.7% |
| Schizophrenia | 34 | 39.1% |
| Schizoaffective disorder | 13 | 14.9% |
| Bipolar disorder I | 22 | 25.3% |
| Duration of baseline hospitalization (days, median, range) | 48 | 7–371 |
| 7–29 days | 28 | 32.2% |
| 30–60 days | 31 | 35.6% |
| ⩾61 days | 28 | 32.2% |
| Number of antipsychotic agents used at discharge (%) | ||
| One antipsychotic agent | 69 | 79.3% |
| ⩾Two antipsychotic agents | 18 | 20.7% |
| Type of antipsychotic medication (%) | ||
| Second generation | 65 | 74.7% |
| First generation | 13 | 15.0% |
| Combination | 9 | 10.3% |
| Department at discharge (%) | ||
| Open unit | 73 | 83.9% |
| Closed unit | 14 | 16.1% |
| First admission (%) | ||
| Yes | 9 | 10.3% |
| No | 78 | 89.7% |
| Residential situation (%) | ||
| Alone | 40 | 46.0% |
| Living with others | 45 | 51.7% |
| Other/homeless | 2 | 2.3 |
| Mean GAF score (SD) | 46.0 | 11.7 |
| History of substance use | ||
| No | 64 | 73.6% |
| Yes | 23 | 26.4% |
SD, standard deviation; GAF, Global Assessment of Functioning scale.
Univariate analysis for the variables of patient/disease and medication characteristics, patients’ attitude towards medicine use and healthcare-professional-rated assessment.
| Variables |
| % rehospitalized | HR (95% CI) |
|---|---|---|---|
|
| 87 | 33.3 | |
|
| |||
|
| 0.99 (0.98–1.00)[ | ||
|
| |||
| Schizophrenia | 34 | 44.1 | Reference |
| Schizoaffective disorder | 13 | 23.1 | 0.49 (0.14–1.71) |
| Brief psychotic disorder | 18 | 33.3 | 0.66 (0.26–1.70) |
| Bipolar disorder I | 22 | 22.7 | 0.44 (0.16–1.20)[ |
|
| |||
| Male | 52 | 34.6 | Reference |
| Female | 35 | 31.4 | 0.99 (0.47–2.01) |
|
| 1.02 (0.99–1.05)[ | ||
|
| |||
| Alone | 40 | 40.0 | Reference |
| Living with others | 45 | 26.7 | 0.62 (0.29–1.31) |
| Other/unknown | 2 | 50.0 | 1.13 (0.15–8.57) |
|
| |||
| No | 64 | 34.4 | Reference |
| Yes | 23 | 30.4 | 0.82 (0.35–1.92) |
|
| |||
| Yes | 9 | 33.3 | Reference |
| No | 78 | 33.3 | 1.03 (0.31–3.40) |
|
| 1.01 (0.98–1.05) | ||
|
| |||
| Open unit | 73 | 32.9 | Reference |
| Closed unit | 14 | 35.7 | 1.01 (0.38–2.64) |
|
| |||
|
| |||
| One antipsychotic agent | 69 | 36.2 | Reference |
| ⩾Two antipsychotic agents | 18 | 22.2 | 0.56 (0.20–1.61) |
|
| |||
| First generation | 13 | 30.8 | 0.72 (0.25–2.06) |
| Second generation | 65 | 38.5 | Reference |
| Combination of both | 9 | 0.0 | NA |
|
| 1.03 (0.99–1.15) | ||
|
| |||
| No | 21 | 19.0 | Reference |
| Yes | 66 | 37.9 | 1.45 (0.87–2.39)[ |
|
| |||
| Yes | 26 | 15.4 | Reference |
| No | 43 | 44.2 | 3.32 (1.13–9.78)[ |
| Now and then | 18 | 33.3 | 2.41 (0.68–8.54)[ |
|
| |||
| Yes | 18 | 22.2 | Reference |
| No | 68 | 36.8 | 1.68 (0.59–4.84) |
| Unknown | 1 | 0.0 | NA |
|
| |||
|
| |||
| Ambivalent | 33 | 18.2 | Reference |
| Skeptical | 18 | 50.0 | 3.38 (1.20–9.50)[ |
| Indifferent | 8 | 25.0 | 1.50 (0.30–7.44) |
| Accepting | 28 | 42.9 | 2.62 (0.98–7.00)[ |
|
| |||
| Harm score[ | 0.92 (0.81–1.04)[ | ||
| Overuse score[ | 1.02 (0.90–1.15) | ||
|
| |||
|
| |||
| Yes | 62 | 37.1 | Reference |
| No | 24 | 25.0 | 0.66 (0.27–1.61) |
| Do not know anymore | 1 | 0.0 | |
|
| |||
| Yes | 64 | 37.5 | Reference |
| No | 22 | 22.7 | 0.58 (0.22–1.52) |
| Do not know anymore | 1 | 0.0 | NA |
|
| |||
| Yes | 71 | 32.4 | Reference |
| No | 15 | 33.3 | 1.06 (0.40–2.79) |
| Do not know anymore | 1 | 100.0 | NA |
|
| |||
| Yes | 65 | 38.5 | Reference |
| No | 21 | 19.0 | 0.45 (0.16–1.30)[ |
| Do not know anymore | 1 | 0.0 | NA |
|
| |||
| Yes | 72 | 37.5 | Reference |
| No | 7 | 0.0 | NA |
| I do not know | 8 | 25.0 | 0.63 (0.15–2.65) |
|
| |||
| Yes | 73 | 35.6 | Reference |
| No | 7 | 42.9 | 1.28 (0.39–4.22) |
| I do not know | 7 | 0.0 | NA |
|
| 1.04 (0.99–1.02) | ||
|
| 1.00 (0.99–1.02) | ||
|
| |||
| Prediction ⩽50% | 60 | 35.0 | Reference |
| Prediction >50% | 27 | 29.6 | 0.77 (0.34–1.75) |
|
| |||
| Prediction ⩽50% | 58 | 25.9 | Reference |
| Prediction >50% | 29 | 48.3 | 2.13 (1.03–4.42)[ |
|
| |||
| Good | 60 | 36.7 | Reference |
| Moderate/bad | 27 | 25.9 | 0.71 (0.30–1.66) |
|
| |||
| Good | 63 | 31.7 | Reference |
| Moderate/bad | 24 | 37.5 | 1.18 (0.54–2.59) |
p < 0.2; **p < 0.05.
Continuous variable.
AP, antipsychotics; BMQ, Beliefs about Medicines Questionnaire; CI, confidence interval; GAF, Global Assessment of Functioning scale; HR, hazard ratio; NA, not applicable.
Results of the multivariate prediction models.
| Variables | |
|---|---|
|
| 0.99 (0.97–0.998)[ |
|
| |
| Schizophrenia | Reference |
| Brief psychotic disorder | 0.83 (0.19–3.57) |
| Schizoaffective disorder | 0.89 (0.16–5.12) |
| Bipolar disorder I | 0.12 (0.02–0.73)[ |
|
| |
| Yes | Reference |
| No | 0.70 (0.01–0.66)[ |
|
| |
| Open unit | Reference |
| Closed unit | 0.30 (0.05–1.77)[ |
|
| |
| First generation | 0.15 (0.03–0.88)[ |
| Second generation | Reference |
| Combination of both | NA |
|
| 1.29 (1.09–1.52)[ |
|
| |
| Yes | Reference |
| No | 11.89 (1.30–108.93)[ |
| Now and then | 1.84 (0.19–18.21) |
|
| |
| Yes | Reference |
| No | 0.08 (0.10–0.64)[ |
| Unknown | NA |
|
| |
| Ambivalent | Reference |
| Skeptical | 6.30 (1.18–33.70)[ |
| Indifferent | 7.23 (0.64–82.19)[ |
| Accepting | 0.96 (0.18–5.20) |
|
| |
| Harm score[ | 0.75 (0.58–0.98)[ |
| Overuse score[ | 1.18 (0.98–1.42)[ |
|
| |
| Yes | Reference |
| No | 0.06 (0.07–0.55)[ |
| Do not know anymore | NA |
|
| |
| Yes | Reference |
| No | 0.07 (0.11–0.43)[ |
| Do not know anymore | NA |
|
| |
| Good | Reference |
| Moderate/bad | 3.27 (0.77–13.89)[ |
|
| 1.04 (1.00–1.07)[ |
|
| 0.82 |
p < 0.2; **p < 0.05.
Continuous variable.
AP, antipsychotics; AUCROC, receiver operating characteristics for area under the curve; BMQ, Beliefs about Medicines Questionnaire; NA, not applicable.
Regression coefficient of the predictors obtained from model 1 + 2 + 3 + 4 with assigned score.
| Predictor | Regression coefficient = score |
|---|---|
|
| −0.014 |
|
| |
| Schizophrenia | Reference |
| Brief psychotic disorder | −0.113 |
| Schizoaffective disorder | −0.190 |
| Bipolar disorder I | −2.115 |
|
| |
| Yes | Reference |
| No | −2.66 |
|
| |
| Open unit | Reference |
| Closed unit | −1.21 |
|
| |
| First generation | −1.88 |
| Second generation | Reference |
| Combination of both | NA |
|
| 0.25 |
|
| |
| Yes | Reference |
| No | 2.48 |
| Now and then | 0.61 |
|
| |
| Yes | Reference |
| No | −2.53 |
| Unknown | NA |
|
| |
| Ambivalent | Reference |
| Skeptical | 1.84 |
| Indifferent | 1.98 |
| Accepting | −0.043 |
|
| |
| Harm score | −0.29 |
| Overuse score | 0.16 |
|
| |
| Yes | Reference |
| No | −2.81 |
| Do not know anymore | NA |
|
| |
| Yes | Reference |
| No | −2.70 |
| Do not know anymore | NA |
|
| |
| Good | Reference |
| Moderate/bad | 1.19 |
|
| |
| Prediction ⩽50% | Reference |
| Prediction >50% | 0.034 |
The score is obtained by rounding each regression coefficient to nearest integer, summing them and adding 8 to the summed risk score.
AP, antipsychotic medication; BMQ, Beliefs about Medicines Questionnaire; NA, not applicable.
Distribution of patients rehospitalized within risk score category.
| Risk score category[ | Total | Patients rehospitalized (%)[ | Median time to rehospitalization (range) | HR (95% CI) |
|---|---|---|---|---|
| 0.0–10.0 | 29 | 20.6 | 24 (15–60) | Reference |
| 10.1–12.3 | 29 | 20.6 | 32 (21–181) | 0.96 (0.31–2.96) |
| 12.4–16.5 | 29 | 58.6 | 42 (12–165) | 3.34 (1.31–8.49)[ |
|
| 87 | 33.3 | 32 (12–181) |
p < 0.05.
The calculated of the total risk score was rounded to nearest integer.
Proportion of patients rehospitalized within each risk score category.
CI, confidence interval; HR, hazard ratio.
Results of the multivariate prediction models for patients with schizophrenia.
| Variables | |
|---|---|
| GAF score | 1.06 (1.00–1.12)[ |
| Age | 1.07 (1.02–1.13)[ |
| Harm score | 0.79 (0.62–1.02)[ |
| AUCROC (6 months) | 0.71 |
p < 0.2; **p < 0.05.
AUCROC, receiver operating characteristics for area under the curve; GAF, Global Assessment of Functioning scale.
Results of the multivariate prediction models for patients without schizophrenia.
| Variables | |
|---|---|
|
| 0.96 (0.92–1.01)[ |
|
| |
| Alone | Reference |
| Living with others | 0.26 (0.075–0.91)[ |
| Other/unknown | 0.78 (0.085–7.24) |
|
| |
| Prediction ⩽50% | Reference |
| Prediction >50% | 3.82 (1.02–14.39)[ |
|
| 1.03 (1.00–1.06)[ |
|
| 0.73 |
p < 0.2; **p < 0.05.
AP, antipsychotics; AUCROC, receiver operating characteristics for area under the curve; GAF, Global Assessment of Functioning scale.